Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2026 | 881 | 0.770 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2026 | 71 | 0.750 |
Why?
|
| Methotrexate | 4 | 2026 | 348 | 0.670 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2026 | 194 | 0.600 |
Why?
|
| Vincristine | 3 | 2017 | 187 | 0.250 |
Why?
|
| Induction Chemotherapy | 1 | 2025 | 54 | 0.220 |
Why?
|
| Neutropenia | 2 | 1996 | 209 | 0.220 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 38 | 0.220 |
Why?
|
| Neoplasms | 3 | 2024 | 2994 | 0.210 |
Why?
|
| Medically Underserved Area | 1 | 2024 | 86 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2025 | 148 | 0.200 |
Why?
|
| Survivorship | 1 | 2023 | 44 | 0.200 |
Why?
|
| Anemia, Sickle Cell | 2 | 1998 | 334 | 0.190 |
Why?
|
| Metabolome | 1 | 2025 | 325 | 0.190 |
Why?
|
| Child, Preschool | 15 | 2026 | 15028 | 0.190 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 45 | 0.190 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 368 | 0.180 |
Why?
|
| Child | 18 | 2026 | 26235 | 0.180 |
Why?
|
| Patient Preference | 1 | 2023 | 150 | 0.170 |
Why?
|
| Metabolomics | 1 | 2025 | 500 | 0.170 |
Why?
|
| Adolescent | 15 | 2026 | 20876 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 707 | 0.170 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2020 | 10 | 0.160 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 2 | 2001 | 29 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2023 | 281 | 0.150 |
Why?
|
| Orbit | 1 | 2020 | 75 | 0.150 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1996 | 91 | 0.150 |
Why?
|
| Infant | 11 | 2026 | 13293 | 0.140 |
Why?
|
| Telemedicine | 1 | 2024 | 525 | 0.130 |
Why?
|
| Caregivers | 1 | 2023 | 596 | 0.130 |
Why?
|
| Dexamethasone | 1 | 1998 | 250 | 0.130 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 50 | 0.130 |
Why?
|
| Methylprednisolone | 2 | 2001 | 94 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 298 | 0.120 |
Why?
|
| Glucocorticoids | 2 | 1995 | 347 | 0.120 |
Why?
|
| Female | 20 | 2026 | 70546 | 0.120 |
Why?
|
| Anemia, Refractory | 1 | 1995 | 7 | 0.120 |
Why?
|
| Brain Neoplasms | 2 | 2023 | 1306 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 248 | 0.110 |
Why?
|
| Hemoglobinuria | 1 | 1995 | 2 | 0.110 |
Why?
|
| Texas | 4 | 2024 | 3661 | 0.110 |
Why?
|
| Fanconi Anemia | 1 | 1995 | 48 | 0.110 |
Why?
|
| Aminophylline | 1 | 1995 | 7 | 0.110 |
Why?
|
| Leukemia, Basophilic, Acute | 1 | 1995 | 4 | 0.110 |
Why?
|
| Ceftriaxone | 1 | 1995 | 69 | 0.110 |
Why?
|
| Male | 16 | 2026 | 64587 | 0.110 |
Why?
|
| Lung Diseases | 1 | 1998 | 396 | 0.110 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1995 | 66 | 0.110 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1994 | 10 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 1995 | 98 | 0.100 |
Why?
|
| Hypoprothrombinemias | 1 | 1993 | 1 | 0.100 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 1993 | 8 | 0.100 |
Why?
|
| Young Adult | 5 | 2026 | 10033 | 0.100 |
Why?
|
| Humans | 25 | 2026 | 130515 | 0.100 |
Why?
|
| Anaphylaxis | 1 | 1995 | 94 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1994 | 124 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1995 | 1604 | 0.090 |
Why?
|
| Genotype | 1 | 2017 | 2589 | 0.080 |
Why?
|
| Hemorrhage | 1 | 1993 | 485 | 0.080 |
Why?
|
| Leukocyte Count | 2 | 1996 | 245 | 0.060 |
Why?
|
| Genomics | 2 | 2024 | 1620 | 0.060 |
Why?
|
| Genetic Services | 1 | 2024 | 9 | 0.050 |
Why?
|
| Syndrome | 2 | 1998 | 1154 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 201 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 1581 | 0.050 |
Why?
|
| Germ Cells | 1 | 2024 | 201 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3422 | 0.050 |
Why?
|
| Self Report | 1 | 2026 | 553 | 0.050 |
Why?
|
| Prognosis | 2 | 2026 | 4866 | 0.050 |
Why?
|
| Machine Learning | 1 | 2025 | 380 | 0.040 |
Why?
|
| Family | 1 | 2024 | 587 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 821 | 0.040 |
Why?
|
| Exome | 1 | 2024 | 1061 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2001 | 220 | 0.040 |
Why?
|
| Hemoglobin C Disease | 1 | 1998 | 2 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 516 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2001 | 1211 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2001 | 261 | 0.040 |
Why?
|
| beta-Thalassemia | 1 | 1998 | 26 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 741 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 889 | 0.030 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 47 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2026 | 5185 | 0.030 |
Why?
|
| Adult | 3 | 2024 | 31115 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2024 | 843 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 1590 | 0.030 |
Why?
|
| Agranulocytosis | 1 | 1996 | 12 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 1998 | 294 | 0.030 |
Why?
|
| Fever | 1 | 1998 | 312 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1126 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 1996 | 45 | 0.030 |
Why?
|
| Pneumocystis Infections | 1 | 1995 | 3 | 0.030 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 1996 | 40 | 0.030 |
Why?
|
| Pneumocystis | 1 | 1995 | 8 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 1998 | 298 | 0.030 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1995 | 45 | 0.030 |
Why?
|
| Acute Disease | 1 | 1998 | 1152 | 0.030 |
Why?
|
| Oxygen | 1 | 1998 | 548 | 0.030 |
Why?
|
| Prospective Studies | 2 | 1996 | 6424 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 1995 | 79 | 0.030 |
Why?
|
| Prednisone | 1 | 1995 | 235 | 0.030 |
Why?
|
| Hemolysis | 1 | 1995 | 86 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 1995 | 27 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1998 | 1613 | 0.030 |
Why?
|
| Splenic Rupture | 1 | 1994 | 3 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1994 | 47 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 1996 | 130 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1995 | 230 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1995 | 207 | 0.030 |
Why?
|
| Adenosine | 1 | 1995 | 116 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1995 | 349 | 0.030 |
Why?
|
| Hemophilia A | 1 | 1994 | 28 | 0.030 |
Why?
|
| Age of Onset | 1 | 1995 | 592 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1994 | 89 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 4057 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1994 | 387 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 1319 | 0.020 |
Why?
|
| Mycoses | 1 | 1994 | 110 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1994 | 288 | 0.020 |
Why?
|
| Health Care Costs | 1 | 1996 | 407 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 1995 | 265 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 1998 | 542 | 0.020 |
Why?
|
| Length of Stay | 1 | 1998 | 1412 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 426 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1996 | 1243 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 1994 | 713 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 1874 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 1998 | 3038 | 0.020 |
Why?
|
| Mutation | 1 | 2023 | 6059 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1994 | 1325 | 0.020 |
Why?
|
| Quality of Life | 1 | 1996 | 2074 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17650 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8602 | 0.010 |
Why?
|
| Middle Aged | 1 | 2023 | 28420 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 1998 | 12851 | 0.010 |
Why?
|
| Coombs Test | 1 | 2001 | 6 | 0.010 |
Why?
|
| Immune Sera | 1 | 2001 | 54 | 0.010 |
Why?
|
| Urine | 1 | 2001 | 89 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 2001 | 120 | 0.010 |
Why?
|
| Nasopharynx | 1 | 2001 | 88 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2001 | 257 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2001 | 782 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 1171 | 0.010 |
Why?
|
| Colloids | 1 | 1994 | 15 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1994 | 119 | 0.010 |
Why?
|
| Biopsy | 1 | 1996 | 1229 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1994 | 313 | 0.010 |
Why?
|
| Recurrence | 1 | 1996 | 1482 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 2061 | 0.000 |
Why?
|
| Time Factors | 1 | 1996 | 6169 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1996 | 3751 | 0.000 |
Why?
|